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Available online 16 September 2014Intracellular cytokine staining (ICS) assay is increasingly used in vaccine clinical trials to measure
antigen-specific T-cell mediated immune (CMI) responses in cryopreserved peripheral blood
mononuclear cells (PBMCs) and whole blood. However, recent observations indicate that several
parameters involved in blood processing can impact PBMC viability and CMI responses, especially
in antiretroviral therapy (ART)-naïve HIV-1-infected individuals.
In this phase I study (NCT01610427), we collected blood samples from22 ART-naïve HIV-1-infected
adults. PBMCs were isolated and processed for ICS assay. The individual and combined effects of the
following parameterswere investigated: time betweenblood collection and PBMCprocessing (time-
to-process: 2, 7 or 24h); time betweenPBMC thawing and initiation of in vitro stimulationwithHIV-
1 antigens (resting-time: 0, 2, 6 and 18 h); and duration of antigen-stimulation in PBMC cultures
(stimulation-time: 6 h or overnight). The cell recovery after thawing, cell viability after ICS and
magnitude of HIV-specific CD8+ T-cell responses were considered to determine the optimal
combination of process conditions. The impact of time-to-process (2 or 4 h) onHIV-specific CD8+ T-
cell responses was also assessed in a whole blood ICS assay.
A higher quality of cells in terms of recovery and viability (up to 81% and N80% respectively) was
obtained with shorter time-to-process (less than 7 h) and resting-time (less than 2 h) intervals.
Longer (overnight) rather than shorter (6h) stimulation-time intervals increased the frequency of
CD8+-specific T-cell responses using ICS in PBMCswithout change of the functionality. The CD8+
specific T-cell responses detected using fresh whole blood showed a good correlation with the
responses detected using frozen PBMCs.Keywords:
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Monitoring antigen-specific T-cell immunity is central in
clinical trials aiming to develop innovative preventative and
therapeutic vaccines (Seder et al., 2008). In order to compare
the immunogenicity of different vaccine candidates between
multiple clinical trials, the standardization of the procedures
used for blood collection, processing, preservation and blood
cell analysis is of utmost importance (Maecker et al., 2005;
Britten et al., 2008; Mallone et al., 2011).
Intracellular cytokine staining (ICS) is a flow cytometry-
based assay increasingly used to identify, quantify and qualify
antigen-specific T-cell mediated immune (CMI) responses in
vaccine clinical trials (Kierstead et al., 2007; Boaz et al., 2009;
Olemukan et al., 2010; Kutscher et al., 2013). The ICS assay
allows rapid quantitation of a large panel of cytokine-
producing cells, while the multi-parameter capability of flow
cytometry allows determination of cell-specific production of
individual cytokines. The ICS assay can be performed using
cryopreserved peripheral blood mononuclear cells (PBMCs)
(Horton et al., 2007) or fresh whole blood (Hanekom et al.,
2004; Meddows-Taylor et al., 2007). The reliable evaluation of
CMI responses requires cell samples that have been properly
prepared. That implies cell samples of good quality, regularly
assessed for the proportion of viable lymphocytes in the
sample before flow cytometry analysis. Previously, it was
shown that the length of time from venipuncture to cryopres-
ervation was the most important parameter influencing T-cell
performance in cellular immune assays, affecting subsequent
cell recovery and function (Bull et al., 2007). Recent observa-
tions indicate that several other parameters involved in blood
processing as well as antigen-stimulation can impact cell
viability and the measured T-cell responses (Owen et al.,
2007; Jeurink et al., 2008; McKenna et al., 2009; Weinberg
et al., 2009; Afonso et al., 2010; Mallone et al., 2011; Kutscher
et al., 2013). Moreover, the sensitivity of whole blood versus
PBMC assays is still under debate, with different studies
reaching opposite conclusions (Suni et al., 1998; Hoffmeister
et al., 2003).
In recent HIV-1 vaccine trials, HIV-1-specific CD4+ and
CD8+ T-cell responses were evaluated by ICS following in vitro
stimulation with p17, p24, reverse transcriptase (RT) and Nef
peptide pools to assess the expression of interleukin-2 (IL-2),
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and
CD40-ligand (CD40L), using PBMCs isolated from venous blood
(Van Braeckel et al., 2011; Harrer et al., 2014). By compiling
previous evaluations, we observed a lower PBMC viability after
ICS in antiretroviral therapy (ART)-naïve HIV-1-infected pa-
tients (ART− HIV+) compared to ART-experienced HIV-1-
infected patients (ART+HIV+) (samples from trial published in
Harrer et al., 2014) or uninfected volunteers (HIV−) (samples
from trial published in Denny et al., 2013) (Fig. 1).
To investigate this further, blood samples were collected
from ART− HIV+ patients and the following parameters were
investigated: (i) timebetweenblood collection andprocessing orcryopreservation of PBMCs (“time-to-process”); (ii) time be-
tween PBMC thawing and initiation of the in vitro stimulation
(“resting-time”); and (iii) duration of antigen-stimulation in
PBMC cultures (“stimulation-time”). The total cell recovery, cell
viability and the magnitude or quality of HIV-specific T-cell
responses were assessed to determine the optimal combination
of process conditions. Additionally, the influence of the “time-to-
process” parameter was evaluated following ICS on fresh whole
blood samples.2. Material and methods
2.1. Study design
This was a phase I, self-contained clinical trial conducted at
the Center for Vaccinology, Ghent University Hospital, Ghent,
Belgium, between June and October 2012. Blood samples were
collected from 22 ART− HIV+ adult participants.
A Design-of-experiments (DoE) statistical approach was
used to evaluate the individual and combined effects of the
quantitative parameters “time-to-process” (TTP) and “resting-
time” (RsT) on the quality of CMI analyses in a response surface
design. Cell recovery and viability were measured in blood
samples during the CMI protocol using the following combina-
tion of experimental conditions: TTP (2, 7 or 24 h) and RsT
(none, 2, 6 or 18 h). Thesemeasurements were used as input in
a polynomial prediction model, to further calculate optimal
combinations for these experimental conditions on cell
viability. The same approach was used for cell recovery and
measurements of CMI responses.
The study was conducted in accordance with the Good
Clinical Practice Guidelines and the Declaration of Helsinki.
Written informed consent was obtained from each partici-
pant prior to the performance of any study-specific proce-
dures. This study has been registered at www.clinicaltrials.
gov (NCT01610427). A summary of the protocol is available at
http://www.gsk-clinicalstudyregister.com (GSK study 116329).2.2. Study participants
Participants were ART− HIV + eligible adults between 18
and 55 years of age at the time of enrollment, who were not
eligible for ART treatment as per established guidelines.
Participants had to have an HIV-1 RNA viral load (VL) level
between and including 2000 and 100,000 copies/mL and a
CD4+ T-cell count N500 cells/μL at screening. Participants who
at screening had any clinically relevant medical condition or
grade 3 or 4 abnormalities as defined by Division of Acquired
Immunodeficiency Syndrome (DAIDS) grading were not
enrolled. No planned hematotoxic, investigational or non-
registered product, nor vaccine not foreseen in the protocol
was allowed during the study period. No pregnant or lactating
women were included in the study.
Fig. 1.Distribution of PBMC viability after ICS in ART− HIV+, ART+ HIV+ and HIV− individuals. % of samples = viability of lymphocytes expressed as a percentage;
ART− HIV+ = antiretroviral therapy (ART)-naïve HIV positive individuals; ART+ HIV+ = ART-experienced HIV positive individuals; HIV− = HIV negative
individuals.
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The primary objective of this study was to model lympho-
cyte viability according to TTP and RsT conditions and to select
the best combination of these two parameters with the aim to
maximize the post-ICS viability in PBMC samples collected
from ART− HIV+ individuals.
The secondary objectives were: (i) to describe the impact of
absence or presence of the resting step before ICS on the
proportion of viable lymphocytes and on the CMI responses in
PBMC samples, and (ii) to describe the proportion of viable
lymphocytes and the magnitude of the CMI responses followingFig. 2. PBMC processing (A), ICS steps and investigated parameters (B). Ag = antigen
liquid N2 = liquid nitrogen; ON= overnight; RT = room temperature.6 h (as compared to overnight) antigen stimulation before ICS.
The impact of TTP and RsT on the total cell recovery has been
evaluated as a post-hoc analysis.
The exploratory objectives were: (i) to describe the
relationship between HIV parameters (HIV-1 VL, CD4+ and
CD8+ T-cell counts), and cell viability and CMI responses for
conditions nearest to the selected best combination of TTP and
RsT; (ii) to describe the relationship between inflammatory
markers (IL-6, D-dimer), and cell viability and CMI responses
for conditions nearest to the selected best combination of TTP
and RsT; and (iii) to evaluate the impact of TTP (2 h vs 4 h) on
the whole blood ICS assay.; BFA = brefeldin A; Bkg = background; ICS = intracellular cytokine staining;
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Blood samples were collected by venipuncture in lithium-
heparin tubes. The tubes were kept at room temperature
(20–25 °C) and shipped immediately to a designated labora-
tory for separation of PBMCs within 2, 7 or 24 h (TTP), in
accordance with current operating procedures (Fig. 2). PBMCs
were separated on Lymphoprep™ gradients, washed, count-
ed by flow cytometry, frozen and further stored in liquid
nitrogen for 9 to 23 weeks. This limited timeframe was not
evaluated as a key parameter in our analysis. HIV-specific
CD4+ and CD8+ T-cell responses were evaluated by ICS
(Fig. 2B), as previously described (Van Braeckel et al., 2011;
Harrer et al., 2014).
Briefly, cryopreserved PBMCs were rapidly thawed and
counted by flow cytometry using propidium iodide to identify
dead cells. Cells were used after thawing without resting or
with a 2, 6 or 18 h RsT, prior to stimulation. Cell recovery was
calculated as the ratio of number of viable cells after thawing
and RsT to number of cells before freezing (cell counts). One
million PBMCswere stimulated in vitro with HIV peptide pools
(15-mer peptides overlapping by 11 amino acids, covering the
sequences of p17, p24, RT or Nef antigens) or medium only in
the presence of anti-CD28/CD49d antibodies (used as co-
stimulatory molecules). After 2 h of stimulation at 37 °C,
brefeldin A was added to inhibit signal molecule secretion
during an additional 4-hour or overnight (16 h) incubation
(Tstim). Cells were harvested, stained for surface markers
(CD4+ and CD8+) in combination with the LIVE/DEAD®
marker, fixed, permeabilized, and stained with labeled anti-
bodies to CD3, CD40L, IL-2, IFN-γ, and TNF-α. Cell viability was
calculated at the end of the ICS process, based on the
percentage of LIVE/DEAD® negative cells in the gate (viable
cells), excluding debris and doublets. The LIVE/DEAD®marker
is based on the reaction of a fluorescent reactive dye with
cellular amines whose expression differs between viable and
necrotic cells.Fig. 3. Whole blood processing and Ag stimulation steps (A), ICS steps and in
ethylenediaminetetraacetic acid; FACS= fluorescence-activated cell sorting; ICS = int
RT = room temperature; SEB = Staphylococcus enterotoxin B.Acquisition was performed on a BD LSRII (Becton Dickin-
son) flow cytometer and data were analyzed using the FlowJo
software v.9.5.2 (Tree Star, Inc.).
2.5. Whole blood processing methods
The impact of TTP on an ICS assay on whole blood was
evaluated as a tertiary objective (Fig. 3). Briefly, within 2 or 4 h
TTP after collection, 350 μL of whole blood was stimulated
in vitro using the abovementioned HIV peptide pools (and
phosphate buffered saline [PBS] or Staphylococcus enterotoxin
B [SEB] as negative and positive controls, respectively), in the
presence of anti-CD28 and anti-CD49d antibodies. Following a
2-hour stimulation at 37 °C, brefeldin A was added to inhibit
signal molecule secretion during an additional overnight
incubation. After EDTA treatment to unstick adherent cells,
red blood cells were then eliminated by fluorescence-activated
cell sorting (FACS) lysing solution and cells were frozen at
−70 °C. Subsequently, samples were thawed and cells were
stained using the ICS procedure (except for the LIVE/DEAD®
marker which was not used in the staining panel), analyzed by
flow cytometry and FlowJo software as described previously
for the ICS assay using PBMCs.
2.6. Statistical methods
The target size was 20 ART− HIV+ adult participants based
on feasibility considerations and power computations. This
sample size allowed concluding on theprimary objectivewith a
power of at least 95% assuming an increase of percentage of
viable lymphocytes of 25%, based on either a regression model
with quantitative factors or a 3-way Analysis of Variance
(ANOVA) mixed model with qualitative factors. The analyses
were performed on the according-to-protocol (ATP) cohort.
To predict the percentage of viable lymphocytes in the CMI
samples, a mixed model for repeated measurements was used,
with TTP and RsT being considered as quantitative factors in avestigated parameters (B). Ag = antigen; BFA = brefeldin A; EDTA =
racellular cytokine staining; ON= overnight; PBS= phosphate buffered saline;
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variance–covariance matrix were determined by maximizing
the prediction efficiency (based on Information Criteria) while
respecting the model hierarchy and preserving all fixed effect
having b10% p-value.
The prediction model was used to display graphically the
predicted impacts of TTP and RsT on cell recovery and viability,
and to calculate their predicted optimal combinations (in order
to maximize the percentage of viable lymphocytes).
For the combination of parameters nearest to the selected
best combination, regression analysis was used to explore the
relationship betweenHIV-1 VL, the CD4+ and CD8+ counts, the
inflammatory markers (IL-6, D-dimer) and the cell recovery/
viability or the magnitude of the CMI response.
Thewhole blood data were analyzedwith anANOVAwith 1
factor (TTP: 2 h vs 4 h) using a heterogeneous variance model,
i.e. identical varianceswere not assumed for the different levels
of the factor. Estimates of the geometric mean ratios (GMRs)
between groups and their 95% confidence intervals (CIs) were
obtained usingback-transformation on log10 values for CD40L+
CD4+ and CD8+ T cells expressing at least one cytokine. The
criteria used to demonstrate equivalence were defined a
posteriori as the 95% CI for the GMR had to be included in the
predefined equivalence limit of [0.3–3].
The ICS resultswere expressed as the percentage of the total
CD40L+ CD4+ and CD8+ T cells expressing the different
combinations of IL-2 and/or IFN-γ and/or TNF-α in response
to stimulation with p17, p24, RT or Nef antigens minus the
response measured upon in vitro stimulation with medium
only.
A Pearson correlation coefficient (r) was used to compare
CD8+ responses of PMBCs vs whole blood.
The statistical analyses were performed using the Statistical
Analysis Systems (SAS) version 9.2 on Windows and StatXact-
8.1 procedure on SAS.
3. Results
3.1. Demographics
A total of 31 participants were screened in this study. Of
these, 22 (71%) participants were included in the ATP cohort
and completed the study. In the ATP cohort, themean age of the
participants was 36.8± 9.1 years, 20 (90.9%) participants were
males and the majority of participants were White-Caucasian
(90.9%).
3.2. ICS using frozen PBMCs
3.2.1. Cell recovery and cell viability
PBMC recovery before ICS was weakly affected by varying
TTP, but declined sharply (cell recovery b50%) after an RsT of
N2 h (Fig. 4A). The predicted optimum of the DoE analysis was
reached for a TTP of 2 h and no RsT, with a predicted mean cell
recovery of 81.5%. A slight increase was observed with a TTP of
24 h or an RsT of 18 h. Further analysis of physical parameters
with Forward and Side Scatter (FSC/SCC) did not show any
differences in proportion of granulocytes or large mononuclear
cells (Supplementary Figure S1) that could have explained
these increases. Additional cell markers should be assessed tobetter characterize the cell phenotypes in these different
conditions.
Lower limit of 95% CI of cell viability N80% was obtained
with a TTP of b7 h and an RsT of b13 h (Fig. 4B). The optimal
predicted response of the DoE analysis in terms of cell viability
(87.5%) was reached for a TTP of 2 h and an RsT of 6.5 h. For a
TTP of 7 h and no RsT, mean cell viability estimated by the
model was 82.9% (95% CI: 80.4%; 85.1%).
3.2.2. HIV-speciﬁc T-cell responses
In this study, the magnitude of the RT-specific response of
CD8+ T cells expressing at least one of the tested cytokines (IL-
2, IFN-γ and TNF-α) was independent of TTP and RsT
parameters, but was higher after overnight compared to 6 h
Tstim (Fig. 5). The increase resulted from a higher antigen
specific responsewithout a change in thebackground response.
Similar observations were made for the 3 other antigens (Nef,
p24 and p17; lower sample sizes), although the magnitude of
the responses varied (Nef N RT N p24 N p17) (data not shown).
A 2 fold decrease was observed between RsT 18 h and 0 h,
however acceptable taking into account the variability of the
assay and improvement of quality of cells at RsT 0 vs 18 h.
The HIV-specific CD8+ T-cell cytokine profile was compa-
rable after the overnight or the 6-hour antigen stimulation
(Tstim) (Fig. 6). The percentages of HIV-specific CD8+ T-cell
responses at a TTP of 7 h differed between cytokines (IFN-γ N
IFN-γ+ TNF-α N TNF-α N IL-2), independently of the RsT and
Tstim parameters.
HIV-specific responses of CD40L+ CD4+ T cells expressing
at least one cytokine were very low compared to CD8+ T cells
and no conclusion could be drawn from the data obtained (data
not shown).
3.2.3. Correlation between HIV parameters/inﬂammatory markers
and viability/CMI
No significant correlations (r between−0.6 and 0.55) could
be observed between the HIV-1 VL, the CD4+ and CD8+ T-cell
counts, the inflammatory markers and the cell recovery/
viability or the magnitude of the CMI response for the specific
combination TTP/RsT that is optimal (data not shown).
3.3. ICS using fresh whole blood
High HIV-specific CD8+ T-cell responses in ART− HIV+
participants could be detected using whole blood ICS. No
significant differences could be highlighted for the HIV-specific
CD8+ T-cell responses between 2 and 4 h of TTP (Table 1).
Equivalence (a posteriori defined as 95% CI of GMR included
in [0.33–3]) was observed for antigens p17, p24 and RT. A GMR
(4 h vs 2 h) of 1.46 [95% CI: 0.46–4.66] was calculated
for antigen Nef. Similar to PBMCs, HIV-specific responses of
CD40L+ CD4+ T cells expressing at least one cytokinewere low
and no conclusion could be drawn from the data obtained
(Supplementary Table 1).
Good correlations (correlation coefficient, r N 0.8) for CD8+
T-cell responses against all antigens could be observed
between whole blood (a TTP of 2 h) and PBMCs (RsT 0 h and
a TTP of 2 h or 7 h), except for p17 in the PBMC assaywith a TTP
of 2 h, due to the lower response to antigen p17 (Fig. 7,
Supplementary Figure S2).
Fig. 4. Effect of time-to-process (TTP) and resting-time (RsT) parameters on PBMC recovery (A) and viability (B).
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The present study was designed to evaluate the effect of
several parameters in blood processing and impacting on PBMC
viability and T-cell responses measured by ICS in samples
collected from ART-naïve HIV-1-infected participants. The
selected assessed parameters were: time between blood
collection and PBMC processing/cryopreservation (TTP), time
between PBMC thawing and initiation of the in vitro stimula-
tion (RsT), and duration of antigen-stimulation in PBMCcultures (Tstim). The total cell recovery, viability, and the
magnitude of HIV-specific T-cell responses were assessed to
determine the optimal combination of these parameters. The
CMI response using PBMCs was compared to the one using
whole blood,which could be perceived as an ex vivo evaluation
of the CMI response.
In our study, cell recovery and viability values were higher
for shorter time intervals between phlebotomy and PBMC
cryopreservation (TTP b 7 h) than for longer time intervals.
With these shorter time intervals, the estimated PBMC viability
Fig. 5.Effect of time-to-process (TTP), resting-time (RsT), and duration of antigen stimulation (Tstim) parameters on the responsemagnitude of HIV-1RT-specific CD8+
T cells expressing at least one cytokine among IL-2, IFN-γ and TNF-α.
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improved, from 40% to more than 80%, corresponding to
similar levels observed in healthy HIV-1 negative and ART-
experienced HIV-1 infected participants (Fig. 1). Similar
findings have already been reported in the literature (Bull
et al., 2007; Kierstead et al., 2007). When comparing blood
from healthy volunteers processed at 8 h vs 24 h (TTP) after
venipuncture in a multi-center study, Bull et al. observed a
modest reduction in PBMC viability when TTP increased, an
important loss in cell recovery (~32%), and a loss in viral
peptide-reactive T-cell frequency (IFN-γ ELISPOT) (36–56%)
(Bull et al., 2007). Similar results were obtained in an HIV-
vaccine trial, in which processing of blood samples within 12 h
compared to longer time intervals, led to three-fold higher T-
cell responses (Kierstead et al., 2007). Granulocyte contamina-
tion in blood stored for prolonged periods at room temperature
has been shown not only to reduce the relative number of T
cells present in PBMCs, but also to inhibit T-cell proliferation
following stimulation in ~75% of samples (McKenna et al.,
2009) and to inhibit IFN-γ ELISPOT responses to CD8+ T-cell
viral epitope peptides (Afonso et al., 2010).
In our study, better cell recovery and viability were predicted
for shorter RsT intervals (b13 h for viability and b2 h forFig. 6. Effect of resting-time (RsT) and duration of antigen stimulation (Tstim) paramete
process of 7 h.recovery), but the HIV-specific CD8+ T-cell cytokine profile was
independent of the RsT parameter. However, several reports
have shown better antigen-specific T-cell responses by IFN-γ
ELISPOT using cryopreserved PBMCs when cells are rested
(overnight) prior to performing the assay (Kierstead et al.,
2007; Britten et al., 2008; Janetzki et al., 2008; Boaz et al., 2009;
Kutscher et al., 2013). It has been suggested that this improve-
mentwas due to the fact that a fraction of cells undergoing death
is eliminatedwith resting, thus allowingmore accurate counts of
viable cells used for the assay and eliminating interference by
non-viable cells, resulting in decreased background noise. On the
other hand, a recent study argues that resting is not a universally
applicable approach to improve the performance of cryopre-
served PBMC for detection of low frequency T-cell responses
(Kuerten et al., 2012), which underlines the importance of
establishing whether resting could benefit immune monitoring
in a specific read-out.
In our case, overnight antigen stimulation (Tstim) com-
pared to the standard 6 h improved the magnitude of the RT-
specific CD8+ T-cell response following ICS on PBMCs, without
affecting the cytokine profile. A previous study has shown that
a PBMC Tstim of 6 h gave the highest values for intracellular
cytokine production (Horton et al., 2007). Another study usingrs on the functionality of HIV-1 RT-specific CD8+ T-cell responses for a time-to-
Table 1
Effect of time-to-process (TTP; 2 h vs 4 h) on HIV-1 RT-speciﬁc CD8+ T-cell
response (ICS on whole blood).
Antigen Time-to-process
(h)
Estimate
(GM)a
95% CI
lower limit
95% CI
upper limit
Nef 2 4747 2062 10,931
4 6950 2836 17,032
GMRb (4 h vs 2 h) 1.464 0.459 4.665
p17 2 2912 1488 5697
4 2385 1094 5201
GMR (4 h vs 2 h) 0.819 0.310 2.164
p24 2 5764 3398 9775
4 5351 3022 9474
GMR (4 h vs 2 h) 0.928 0.445 1.937
RT 2 3933 2031 7614
4 3786 2268 6321
GMR (4 h vs 2 h) 0.963 0.433 2.142
GM = geometric mean; GMR = geometric mean ratio; CI = confidence
interval.
a Number of CD8+ T cells expressing at least one cytokine/106 CD8 cells.
b Ratio between the values at 4 h and 2 h.
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stimulation was 18 h (Hanekom et al., 2004).
The ICS assay onwhole bloodwas previously developed and
used in several clinical trials (Agnandji et al., 2011; Day et al.,
2013; Harenberg et al., 2013). An advantage of using whole
blood instead of PBMCs is the smaller sample volumes needed
when blood is used without preliminary PBMC purification,
making this type of assay particularly attractive in children, inFig. 7. Correlation between CD8+ responses of PBMCs (a resting-time of 0 h asettings where testing at frequent time intervals is planned or
for trials conducted in areas with high HIV endemicity, where
access to liquid nitrogen might be problematic (Agnandji et al.,
2011; Mallone et al., 2011; Day et al., 2013; Harenberg et al.,
2013).
Given the good correlations for CD8+ T-cell responses
between ICS performed on whole blood compared to frozen
PBMCs, we have demonstrated that the whole blood ICS assay
is a valid tool to study HIV-1-infected individuals. The
performance of PBMC vs whole blood T-cell assays has been
previously assessed, with contradictory findings. Suni et al.
showed that the whole blood method consistently yielded
higher T-cell frequencies than the method using purified
PBMCs (Suni et al., 1998). However, Hoffmeister et al. obtained
higher T-cell frequencies with PBMCs than with whole blood,
and the responses were sometimes detected only with PBMCs
(Hoffmeister et al., 2003).
Our study revealed no significant differences for HIV-
specific CD8+ T-cell response between 2 and 4 h of TTP using
whole blood, although in the case of ICS, TTP has been shown to
affect assay performance critically, already at 1 h after drawing,
with a marked effect on IFN-γ (Petrovsky and Harrison, 1995).
This study is limited by the fact that the effect of the ICS
parameters on CD4+ T-cell responses was not interpretable
since these responses were low andmasked by the CD8+ T-cell
responses, regardless of using frozen PBMCs or fresh whole
blood. This is not surprising since the participants in the current
study were HIV-1 infected and not vaccinated against HIV-1nd a time-to-process of 7 h) vs whole blood (a time-to-process of 2 h).
9P. Bourguignon et al. / Journal of Immunological Methods 414 (2014) 1–10(Harrer et al., 2014). Also, the conclusions of this study are
restricted to non-vaccinatedART−HIV+participantswhere the
PBMC viability was shown to be the lowest.
5. Conclusions
In samples collected from HIV+ ART− participants, a higher
quality of cells in terms of viability and recovery was observed
when shorter time intervals between phlebotomy and PBMC
cryopreservation (less than 7 h), and between PBMC thawing
and antigen-stimulation (less than 2 h) were used to assess
antigen-specific T-cell responses using ICS. The peak response
of theDoE analysis in terms of cell viability (87.5%)was reached
for a TTP of 2 h and an RsT of 6.5 h. Longer (overnight) rather
than shorter (6 h) duration of antigen-stimulation increased
the observed frequencies of specific T-cell responses without
changing the functionality.
High HIV-1 specific CD8+ T-cell responses were detected
with ICS using fresh whole blood, with a good correlation with
the CMI responses detected using PBMCs. The current whole
blood ICS method could be applied in cases of HIV-1 infection.
This could potentially be of interest for trials conducted in
resource-limited settings (no liquid nitrogen required) or in
infants (small blood volumes).
Our results support the need to use standardized proce-
dures for the evaluation of CMI responses in the field of vaccine
development (and particularly for HIV vaccine development),
and describe an alternative whole blood assay when liquid
nitrogen is not easily available and blood volumes are small.
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